[Test of 0,0-dimethyl (l-hydroxy-2,2,2-trichloroethyl)-phosphonate (trichlorfon) for carcinogenic activity in mice by oral (oesophageal-gastric intubation), intraperitoneal and dermal application (author's transl)].

0,0-Dimethyl(1-hydroxy-2,2,2-trichloroethyl)-phosphonate (Trichlorfon; TCP) was tested for carcinogenic activity in male and female mice derived from strain AB/Jena by oral (oesophageal-gastric intubation), intraperitoneal and dermal administration. The maximum period of treatment was 73 (oral), 73 (intraperitoneal) or 75 (dermal) weeks. During this period the following maximum mean total doses of TCP per animal had been administered: 157.5 mg(male, oral), 154 mg (female, oral), 160.8 mg (male, intraperitoneal), 149.7 mg (female, intraperitoneal). The dermally treated male and female mice had received a maximum total dose of 375 mg per animal. The study was terminated at 80 weeks. There is no statistic significant difference when compared the total tumour incidence of TCP-treated animals and control mice or the incidence of the different corresponding groups of mice separated by the route of administration or the incidence of malignant and benign tumours separated for the different groups. These findings were independent from whether the groups of TCP-treated animals and solvent control animals were combined or divided by sex for comparison.